bluebird bio Inc.

Market Data

S&P 500 Movers

CI -1,3

The range dropdown markets

Latest News All Times Eastern

Scroll up to scroll down

Sectors
Nasdaq

Volume: 15.61M Avg. 65-Day Volume: 3.79M

421% vs Average 2.9500 Day range 3.7400 2.8650 Week Range 8.800

Partner Center

Your Watchlists

Recent Tickers

Key Data

Shorted % of Float 20.60%
Average Volume 3.79M

The Performance of a

5 Day

-22.26%

One Month

-34.74%

Three Months

-49.39%

Year to Date

-51.81%

One Year

-32.35%

Press Releases on Other News

S&P 500 Up 1%; Bluebird Bio Shares Plummet

29.2023 at 2:56 pm ET on Benzinga.com ET on Benzinga.com

Twelve Health Care Stocks Moved In The Intraday Trading Session On Wednesday

29th, 2023 at 12:31 pm ET on Benzinga.com ET on Benzinga.com

Why Kodiak Sciences Stocks are Trading Higher by 18%? What Other Stocks Moved In Wednesday's Midday Session?

29th, 2023 12:50 PM ET on Benzinga.com ET on Benzinga.com

Nasdaq rises 1%, US Pending Home Sales Rise in February

29th, 2023 12:13 PM ET on Benzinga.com ET on Benzinga.com

Why Bluebird Bio Shares Are Plunging Today

29th, 2023 at 11 a.m. ET on Benzinga.com

UniFirst, Progress Software and SomaLogic, among other large stocks, are moving lower on Wednesday

Mar. 29, 2023, 10:36 am ET on Benzinga.com ET on Benzinga.com

Dow jumps over 200 points as US stocks open higher

29.2023 at 9:53 am ET on Benzinga.com ET on Benzinga.com

Twelve Health Care Stocks Moved In The Wednesday Pre-Market Session

29th, 2023 at 9 a.m. ET on Benzinga.com

Bluebird Bio (BLUE) Reports Q4 Loss, Misses Revenue Estimates

29th, 2023 at 8 a.m. ET on Zacks.com

The BLUE turns red on Q4 Misses and Delays in Gene Therapy Application

29th, 2023 at 7 a.m. TipRanks.com

28th, 2023 at 11 a.m. ET on Benzinga.com

Strength Seen in Seattle Genetics SGEN: Can its 14.5% jump translate into more strength?

14th, 2023 at 5:53 a.m. ET on Zacks.com

Clene Inc. (CLNN) Reports Q4 Loss, Tops Revenue Estimates

13th, 2023 at 8:25 am. ET on Zacks.com

The high price of new drugs for cancer and rare diseases puts pressure on the annual increase in older drugs

10th, 2023 at 1:10 p.m. ET on Benzinga.com

Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Tops Revenue Estimates

9th, 2023 at 6 p.m. ET on Zacks.com

Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023

Bluebird Bio (BLUE), Expected To Beat Earnings Forecasts: What You Need to Know Before Q4 Release

On February 24, 2023, at 10:00 am ET on Zacks.com ET on Zacks.com

One Stock that is a Beaten Down but Has Much to Prove by 2023

February 8, 2023, 8:05 am ET ET on Motley Fool

Biotech Stocks Roundup: BLUE Falls on Share Issue, CPRX Drops on Generic Filing & More

Jan. 25, 2020 at 10:53 am. ET on Zacks.com

bluebird bio Inc.

bluebird bio, Inc., a biotechnology company in clinical stages, is engaged in the development and testing of gene therapies to treat cancers and severe genetic diseases. Its integrated platform includes gene therapies, cancer immunotherapy, and gene editing. The company's product pipeline includes Lenti-D and LentiGlobin as well as BCL11a ShRNA, bb2121, bb21217, bb2121, bb21217, and BCL11a. The company was founded on April 16, 1992 by Philippe Leboulch, Ronald C. Dorazio and has its headquarters in Somerville.

Competitors

Merck & Co. Inc. -1.3% $271.45B